Krystal Biotech, INC 8-K filings

Krystal Biotech announced robust second quarter 2026 financial and operating results, highlighted by significant global revenue growth for VYJUVEK and promising updates across its diverse clinical pipeline.

Krystal Biotech disclosed positive single-patient data for its investigational gene therapy KB801, showing complete closure of a persistent corneal epithelial defect.

Krystal Biotech reported robust first-quarter 2026 financial and operating results, driven by significant global revenue growth for its VYJUVEK treatment and progress across its pipeline programs.

Krystal Biotech reported robust financial results for Q4 and full year 2025, driven by strong VYJUVEK revenue and significant pipeline advancements.

Krystal Biotech announced preliminary unaudited 2025 financial results, including strong VYJUVEK net product revenue, and detailed its rare disease strategic vision and 2026 corporate objectives.

Krystal Biotech announces successful wild-type CFTR delivery and expression in cystic fibrosis patients' lungs from its CORAL-1 study, advancing its mutation-agnostic gene therapy.

Krystal Biotech announces the resignation of Kirti Ganorkar from its Board of Directors, effective December 31, 2025, citing time constraints from a new role at Sun Pharma.

Krystal Biotech reported strong third-quarter 2025 financial results, driven by significant VYJUVEK revenue and international expansion, alongside positive pipeline advancements.

Krystal Biotech's subsidiary, Krystal Biotech Japan KK, commenced the commercial launch of VYJUVEK in Japan for dystrophic epidermolysis bullosa, following its inclusion on the NHI Drug Price List.

Krystal Biotech reports robust second-quarter 2025 financial results, driven by strong VYJUVEK revenue and significant progress in global approvals and pipeline development.

Krystal Biotech announced that Japans Ministry of Health, Labour and Welfare has granted marketing authorization for VYJUVEK, its gene therapy for Dystrophic Epidermolysis Bullosa, marking a significant expansion into the Asian market.

Jeune Aesthetics, a Krystal Biotech subsidiary, announced positive safety and efficacy results from its Phase 1 PEARL-2 study of KB304 for moderate to severe dcollet wrinkles, showing significant aesthetic improvements and a favorable safety profile.

Krystal Biotech announced the dosing of the first patient in its Phase 1/2 EMERALD-1 clinical trial for KB801, an investigational eye drop gene therapy for neurotrophic keratitis.

Krystal Biotech, Inc. announced compelling efficacy and safety data from the monotherapy cohort of its Phase 1/2 clinical trial of inhaled KB707 for advanced solid tumors affecting the lungs, highlighted at the 2025 ASCO Annual Meeting.

Krystal Biotech held its 2025 Annual Meeting of Stockholders on May 16, 2025, and announced the results of the votes on the proposals.

Krystal Biotech's HSV-1-based gene therapy platform shows potential for treating Hailey-Hailey and Darier diseases, with KB111 and KB112 demonstrating successful keratinocyte transduction and ATPase expression in preclinical studies.

Krystal Biotech announces positive Q1 2025 financial results, highlighted by VYJUVEK's European approval and significant revenue growth.

Krystal Biotech's KB801 gene therapy shows promise for sustained nerve growth factor expression in wounded murine corneas, offering a potential topical treatment for neurotrophic keratitis.

Krystal Biotech's VYJUVEK has been approved by the European Commission for treating Dystrophic Epidermolysis Bullosa (DEB) in patients from birth.

Krystal Biotech's VYJUVEK receives a positive recommendation from the European Medicines Agency's CHMP for treating dystrophic epidermolysis bullosa, paving the way for potential EU approval.

Krystal Biotech announces impressive fourth quarter and full-year 2024 financial results, driven by strong VYJUVEK sales and pipeline progress.

Krystal Biotech reports encouraging initial clinical data for its inhaled KB707 therapy, showing monotherapy activity in heavily pre-treated patients with advanced non-small cell lung cancer.

Krystal Biotech reports early clinical success with its inhaled gene therapies KB408 and KB407, showing gene delivery to the lung and increased therapeutic protein levels in patients with rare respiratory diseases.

Krystal Biotech announced strong third-quarter 2024 financial results, highlighted by $83.8 million in net product revenue and significant progress in its clinical pipeline and global expansion efforts.

Jeune Aesthetics, a subsidiary of Krystal Biotech, reported positive interim results from its Phase 1 PEARL-1 study of KB301, an injectable treatment for wrinkles, showing significant improvements in both lateral canthal lines and dynamic wrinkles of the dcollet.

Krystal Biotech announced a successful second quarter of 2024, highlighted by significant revenue growth from VYJUVEK and advancements in their clinical pipeline.

Krystal Biotech held its 2024 Annual Meeting of Stockholders, where key proposals including the election of directors and ratification of the accounting firm were approved.

Krystal Biotech presented data at the ARVO 2024 meeting demonstrating the potential of their HSV-1 vector platform for localized gene delivery to the posterior of the eye.

Krystal Biotech announced a successful first quarter of 2024, highlighted by $45.3 million in net product revenue from VYJUVEK and advancements in its clinical pipeline.

Krystal Biotech announced positive financial results for 2023, driven by the commercial launch of VYJUVEK, and provided updates on its clinical pipeline.